aflutinib

an irreversible tyrosine kinase inhibitor that selectively inhibits EGFR mutations, especially T790M

Also Known As:

AST2818; Ivesa; N-(2-(2-(dimethylamino)ethyl-methylamino)-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide; furmonertinib; furmonertinib mesylate

Networked: 23 relevant articles (10 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - aflutinib: 23
  - Pyridines: 88
    - aflutinib: 23
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - aflutinib: 23

Experts

1.	Jiang, Yong: 4 articles (11/2022 - 01/2021)
2.	Cheng, Ying: 2 articles (11/2022 - 01/2021)
3.	Gu, Chuan: 2 articles (11/2022 - 01/2021)
4.	Liu, Chunling: 2 articles (11/2022 - 01/2021)
5.	Liu, Fei: 2 articles (11/2022 - 07/2022)
6.	Shi, Yuankai: 2 articles (11/2022 - 01/2021)
7.	Wang, Xiang: 2 articles (11/2022 - 01/2021)
8.	Wu, Lin: 2 articles (11/2022 - 01/2021)
9.	Yang, Nong: 2 articles (11/2022 - 07/2021)
10.	Zhang, Shucai: 2 articles (11/2022 - 01/2021)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/01/2023 - "A phase Ib study (FAVOUR, NCT04858958) initially demonstrated the efficacy of furmonertinib in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins). " 08/01/2023 - "A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations." 01/01/2023 - "We report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with EGFR T790M mutated non-small cell lung cancer (NSCLC) from two phase 2 studies. " 01/01/2021 - "This study aimed to assess the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC). " 02/01/2022 - "Furmonertinib was designed for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. "
2.	Neoplasm Metastasis (Metastasis) 01/01/2022 - "In this article, we reviewed the clinical activity and adverse events of furmonertinib at 80 mg daily (approved dose), potential usage of 160 mg daily for CNS metastasis in EGFR+ NSCLC, and usage of 160 mg or 240 mg daily in EGFR exon20 insertion positive (EGFRex20ins+) NSCLC patients." 01/01/2023 - "Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review." 11/01/2022 - "Furmonertinib first-line treatment was found to have superior efficacy in CNS progression-free survival, CNS objective response rate, and CNS depth of response compared with gefitinib in patients with EGFR-mutated NSCLC with CNS metastases." 01/01/2022 - "The third-generation TKIs, like osimertinib and furmonertinib, can reach higher concentration in the cerebrospinal fluid (CSF) than other TKIs, and exhibit a beneficial effect in NSCLC patients with leptomeningeal metastases (LM) harboring sensitive EGFR mutation. " 11/01/2022 - "Eligible patients were stratified according to EGFR mutation (exon 19 deletions or exon 21 Leu858Arg) and CNS metastases (with or without) and randomly assigned (1:1) to receive either oral furmonertinib (80 mg/day) or oral gefitinib (250 mg/day) in 21-day cycles until disease progression, the occurrence of intolerable toxicities, withdrawal of consent, or other discontinuation reasons judged by the investigators. "
3.	Neoplasms (Cancer) 01/01/2022 - "After 2 weeks of furmonertinib, the patient's tumor was markedly smaller on a follow-up chest CT scan, and her respiratory symptoms also improved. " 01/01/2023 - "We administered furmonertinib and observed tumor shrinkage, decreased CA19-9. " 09/12/2023 - "Given the encouraging results, we propose that furmonertinib should be explored as a potential candidate for combination therapy in patients with tumors that have high levels of ABCB1 and/or ABCG2. " 01/01/2023 - "Conclusion: Based on these analyses of survival benefits, tumor burden response, and safety, furmonertinib (Fur), Osi, and aumolertinib (Aum) may represent the best treatment regimen options for Asian patients, significantly prolonging survival (as measured by median PFS/OS), eliciting a greater tumor burden response, and exposing patients to a lower risk of adverse events. " 09/12/2023 - "Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells."
4.	Adenocarcinoma of Lung 01/01/2022 - "Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review." 11/01/2023 - "Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion." 01/01/2023 - "Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report." 03/01/2022 - "Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report." 01/01/2023 - "To the best of our knowledge, this case firstly reported the encouraging efficacy of combined furmonertinib and anlotinib in an advanced lung adenocarcinoma patient with an EGFR exon 20 insertion mutation who was previously treated with platinum-based chemotherapy. "
5.	Lethargy 01/01/2023 - "After 5 days of furmonertinib therapy, the patient recovered from lethargy, with an obvious improvement in cognitive function. "

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	aumolertinib
3.	aflutinib
4.	Gefitinib (Iressa)
5.	osimertinib
6.	ErbB Receptors (EGF Receptor)
7.	Platinum
8.	anlotinib
9.	mobocertinib

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Salvage Therapy